MedTrace Logo

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

NCT06342466 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-12-30

No results posted yet for this study

Summary

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.

Conditions

  • Systemic Amyloidosis

Interventions

DRUG

Bortezomib

Bortezomib 1.3mg/m2 sc weekly

DRUG

Pomalidomide

4mg per day taken orally on 1-21 of repeated 28-day cycles

DRUG

Dexamethasone

Dexamethasone 20mg-40mg weekly

Sponsors & Collaborators

  • Jin Lu, MD

    lead OTHER

Principal Investigators

  • Jin Lu · Peking University People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06342466 on ClinicalTrials.gov